Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy

BACKGROUND Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes o...

Full description

Saved in:
Bibliographic Details
Published in:Medical science monitor 2020-09, Vol.26, p.e922576-e922576
Main Authors: Zeng, Xianghua, Zhu, Shicong, Xu, Cheng, Wang, Zhongyu, Su, Xingxing, Zeng, Dong, Long, Haixia, Zhu, Bo
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - drug therapy
Clinical Research
Comorbidity
Female
Humans
Immune Checkpoint Inhibitors - therapeutic use
Lung Neoplasms - drug therapy
Male
Middle Aged
Progression-Free Survival
Retrospective Studies
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes of patients with NSCLC treated with immune checkpoint inhibitors. MATERIAL AND METHODS Sixty-six patients with NSCLC who received programmed cell death protein 1 (PD1) inhibitors in our institution in the past 2 years were enrolled in this retrospective study. Data on comorbidity (CCI and SCS) and clinical outcomes, including progression-free survival (PFS), immunotherapy responses, and immunotherapy-related adverse events, were analyzed. RESULTS The disease control rate was obviously higher among patients in the CCI
ISSN:1643-3750
1234-1010
1643-3750
DOI:10.12659/MSM.922576